The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis
- PMID: 11156641
- PMCID: PMC1728215
- DOI: 10.1136/gut.48.2.206
The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis
Abstract
Background: Small intestinal bacterial overgrowth may contribute to the development of non-alcoholic steatohepatitis, perhaps by increasing intestinal permeability and promoting the absorption of endotoxin or other enteric bacterial products.
Aims: To investigate the prevalence of small intestinal bacterial overgrowth, increased intestinal permeability, elevated endotoxin, and tumour necrosis factor alpha (TNF-alpha) levels in patients with non-alcoholic steatohepatitis and in control subjects.
Patients and methods: Twenty two patients with non-alcoholic steatohepatitis and 23 control subjects were studied. Small intestinal bacterial overgrowth was assessed by a combined (14)C-D-xylose and lactulose breath test. Intestinal permeability was assessed by a dual lactulose-rhamnose sugar test. Serum endotoxin levels were determined using the limulus amoebocyte lysate assay and TNF-alpha levels using an ELISA.
Results: Small intestinal bacterial overgrowth was present in 50% of patients with non-alcoholic steatosis and 22% of control subjects (p=0.048). Mean TNF-alpha levels in non-alcoholic steatohepatitis patients and control subjects were 14.2 and 7.5 pg/ml, respectively (p=0.001). Intestinal permeability and serum endotoxin levels were similar in the two groups.
Conclusions: Patients with non-alcoholic steatohepatitis have a higher prevalence of small intestinal bacterial overgrowth, as assessed by the (14)C-D-xylose-lactulose breath test, and higher TNF-alpha levels in comparison with control subjects. This is not accompanied by increased intestinal permeability or elevated endotoxin levels.
Comment in
-
Is bacterial ash the flash that ignites NASH?Gut. 2001 Feb;48(2):148-9. doi: 10.1136/gut.48.2.148. Gut. 2001. PMID: 11156629 Free PMC article. No abstract available.
-
Alcohol, obesity, and TNF-alpha.Gut. 2001 Aug;49(2):313-4. doi: 10.1136/gut.49.2.313. Gut. 2001. PMID: 11476082 Free PMC article. No abstract available.
-
Is coeliac disease a confounding factor in the diagnosis of NASH?Gut. 2001 Oct;49(4):596. doi: 10.1136/gut.49.4.596. Gut. 2001. PMID: 11589191 Free PMC article. No abstract available.
-
Small intestinal bacterial overgrowth, intestinal permeability, and non-alcoholic steatohepatitis.Gut. 2002 Jan;50(1):136-8. doi: 10.1136/gut.50.1.136-a. Gut. 2002. PMID: 11772983 Free PMC article. No abstract available.
Similar articles
-
Susceptibility to gut leakiness: a possible mechanism for endotoxaemia in non-alcoholic steatohepatitis.Liver Int. 2008 Aug;28(7):1026-33. doi: 10.1111/j.1478-3231.2008.01723.x. Epub 2008 Apr 7. Liver Int. 2008. PMID: 18397235 Free PMC article.
-
Ciprofloxacin suppresses bacterial overgrowth, increases fasting insulin but does not correct low acylated ghrelin concentration in non-alcoholic steatohepatitis.Aliment Pharmacol Ther. 2005 Aug 15;22(4):291-9. doi: 10.1111/j.1365-2036.2005.02562.x. Aliment Pharmacol Ther. 2005. PMID: 16097995 Clinical Trial.
-
Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis.Am J Physiol Gastrointest Liver Physiol. 2007 Feb;292(2):G518-25. doi: 10.1152/ajpgi.00024.2006. Epub 2006 Oct 5. Am J Physiol Gastrointest Liver Physiol. 2007. PMID: 17023554
-
Role of non-steroidal anti-inflammatory drugs on intestinal permeability and nonalcoholic fatty liver disease.World J Gastroenterol. 2017 Jun 14;23(22):3954-3963. doi: 10.3748/wjg.v23.i22.3954. World J Gastroenterol. 2017. PMID: 28652650 Free PMC article. Review.
-
Probiotics: a potential _target for the prevention and treatment of steatohepatitis.J Clin Gastroenterol. 2004 Jul;38(6 Suppl):S121-2. doi: 10.1097/01.mcg.0000128934.53920.1d. J Clin Gastroenterol. 2004. PMID: 15220676 Review.
Cited by
-
Kupffer Cells in Non-alcoholic Fatty Liver Disease: Friend or Foe?Int J Biol Sci. 2020 Jun 23;16(13):2367-2378. doi: 10.7150/ijbs.47143. eCollection 2020. Int J Biol Sci. 2020. PMID: 32760204 Free PMC article. Review.
-
Kupffer Cells Sense Free Fatty Acids and Regulate Hepatic Lipid Metabolism in High-Fat Diet and Inflammation.Cells. 2020 Oct 8;9(10):2258. doi: 10.3390/cells9102258. Cells. 2020. PMID: 33050035 Free PMC article.
-
New medical treatment strategies for nonalcoholic steatohepatitis.Curr Treat Options Gastroenterol. 2015 Jun;13(2):259-73. doi: 10.1007/s11938-015-0053-z. Curr Treat Options Gastroenterol. 2015. PMID: 25794572
-
Volatile Oil of Amomum villosum Inhibits Nonalcoholic Fatty Liver Disease via the Gut-Liver Axis.Biomed Res Int. 2018 Jul 19;2018:3589874. doi: 10.1155/2018/3589874. eCollection 2018. Biomed Res Int. 2018. PMID: 30112382 Free PMC article.
-
Excess Alcohol Consumption: A Potential Mechanism Behind the Association Between Small Intestinal Bacterial Overgrowth and Coronary Artery Disease.Dig Dis Sci. 2018 Dec;63(12):3516-3517. doi: 10.1007/s10620-018-5279-x. Epub 2018 Oct 26. Dig Dis Sci. 2018. PMID: 30367306 No abstract available.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical